How to Cite
Abstract
Introduction: Multiple myeloma is a monoclonal gammopathy that requires adequate characterization. Magnetic resonance imaging is part of the diagnostic algorithm for this disease; however, the 99mTc sestamibi whole body scan can also assess metabolically active lesions on a total body scan.
Aim: To describe the bone lesions detected by 99mTc-sestamibi and MRI in patients with multiple myeloma.
Materials and methods: A descriptive and retrospective case series study of patients with multiple myeloma was carried out. The clinical characteristics and lesions of patients with multiple myeloma were described, considering the anatomical site and pattern in segmented magnetic resonance imaging of the spine and pelvis and 99mTc-sestamibi images.
Results: The series of patients was characterized by presenting the diffuse pattern in the spine and extramedullary focal pattern both in MRI and in 99mTc-sestamibi, however, 99mTc-sestamibi has the advantage of detecting other anatomical sites in a single total body scan.
Conclusion: 99mTc-sestamibi imaging may be an option in patients with multiple myeloma due to its ability to detect metabolically active disease of the whole body.
References
Kumar SK, Rajkumar SV. The multiple myelomas — current concepts in cytogenetic classification and therapy. Nature Reviews Clinical Oncology [Internet]. 23 de abril de 2018 [consultado el 17 de marzo de 2022];15(7):409-21. Disponible en: https://doi.org/10.1038/s41571-018-0018-y
Tosi P. Diagnosis and Treatment of Bone Disease in Multiple Myeloma: Spotlight on Spinal Involvement. Scientifica [Internet]. 2013 [consultado el 17 de marzo de 2022];2013:1-12. Disponible en: https://doi.org/10.1155/2013/104546
NICE | The National Institute for Health and Care Excellence [Internet]. Overview | Myeloma: diagnosis and management | Guidance | NICE; 18 de febrero de 2016 [consultado el 18 de marzo de 2022]. Disponible en: https://www.nice.org.uk/guidance/ng35
Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology [Internet]. Marzo de 2021 [consultado el 17 de marzo de 2022];32(3):309-22. Disponible en: https://doi.org/10.1016/j.annonc.2020.11.014
Durie BG, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer [Internet]. Septiembre de 1975 [consultado el 18 de marzo de 2022];36(3):842-54. Disponible en: https://doi.org/10.1002/1097-0142(197509)36:3%3C842::aid-cncr2820360303%3E3.0.co;2-u
Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile)technetium(I) in cultured mouse fibroblasts. J Nucl Med. [Internet]. Octubre 1990[consultado el 18 de marzo de 2022];31(10):1646–53. Disponible en: https://pubmed.ncbi.nlm.nih.gov/2213187/
Mele A, Offidani M, Visani G, Marconi M, Cambioli F, Nonni M, Catarini M, Brianzoni E, Berbellini A, Ascoli G, Brunori M, Agostini V, Corvatta L, Isidori A, Spinelli A, Gradari M, Leoni P. Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans. British Journal of Haematology [Internet]. Marzo de 2007 [consultado el 18 de marzo de 2022];136(5):729-35. Disponible en: https://doi.org/10.1111/j.1365-2141.2006.06489.x
Fechtner K, Hillengass J, Delorme S, Heiss C, Neben K, Goldschmidt H, Kauczor HU, Weber MA. Staging Monoclonal Plasma Cell Disease: Comparison of the Durie-Salmon and the Durie-Salmon PLUS Staging Systems. Radiology [Internet]. Octubre de 2010 [consultado el 18 de marzo de 2022];257(1):195-204. Disponible en: https://doi.org/10.1148/radiol.10091809
Moulopoulos LA, Varma DG, Dimopoulos MA, Leeds NE, Kim EE, Johnston DA, Alexanian R, Libshitz HI. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology [Internet]. Diciembre de 1992 [consultado el 18 de marzo de 2022];185(3):833-40. Disponible en: https://doi.org/10.1148/radiology.185.3.1438772
Schmidt GP, Baur A, Stäbler A, Schoenberg SO, Steinborn M, Baltin V, Reiser MF. Beurteilbarkeit diffuser Knochenmarksinfiltrationen der Wirbelsäule bei multiplem Myelom: Korrelation von MRT-Befunden mit der Histologie. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren [Internet]. Abril de 2005 [consultado el 18 de marzo de 2022];177(05):745-50. Disponible en: https://doi.org/10.1055/s-2005-857869
Myslivecek M, Nekula J, Bacovsky J, Scudla V, Koranda P, Kaminek M. Multiple myeloma: predictive value of Tc-99m MIBI scintigraphy and MRI in its diagnosis and therapy. Nucl Med Rev Cent East Eur [Internet]. 2008[consultado el 18 de marzo de 2022];11(1):12–6. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19173182
Bruns I, Cadeddu RP, Brueckmann I, Fröbel J, Geyh S, Büst S et al. Multiple myeloma–related deregulation of bone marrow–derived CD34+ hematopoietic stem and progenitor cells. Blood [Internet]. 27 de septiembre de 2012 [consultado el 18 de marzo de 2022];120(13):2620-30. Disponible en: https://doi.org/10.1182/blood-2011-04-347484
Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia [Internet]. 5 de junio de 2008 [consultado el 18 de marzo de 2022];22(8):1485-93. Disponible en: https://doi.org/10.1038/leu.2008.131
Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F, Catalano L, Liuzzi R, Rotoli B, Del Vecchio S, Pace L, Salvatore M. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma. Journal of Nuclear Medicine [Internet]. 1 de febrero de 2008 [consultado el 18 de marzo de 2022];49(2):195-200. Disponible en: https://doi.org/10.2967/jnumed.107.045641
Bacovsky J, Myslivecek M, Scudla V, Koranda P, Buriankova E, Minarik J, Pika T, Zapletalova J. Tc-99m MIBI Scintigraphy in Multiple Myeloma. Clinical Nuclear Medicine [Internet]. Septiembre de 2010 [consultado el 18 de marzo de 2022];35(9):667-70. Disponible en: https://doi.org/10.1097/rlu.0b013e3181e9f92e
Tirovola E, Biassoni L, Britton K, Kaleva N, Kouykin V, Malpas J. The use of 99mTc-MIBI scanning in multiple myeloma. British Journal of Cancer [Internet]. Diciembre de 1996 [consultado el 18 de marzo de 2022];74(11):1815-20. Disponible en: https://doi.org/10.1038/bjc.1996.636
Bäuerle T, Hillengass J, Fechtner K, Zechmann CM, Grenacher L, Moehler TM, Christiane H, Barbara WG, Neben K, Kauczor HU, Goldschmidt H, Delorme S. Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Importance of Whole-Body versus Spinal MR Imaging. Radiology [Internet]. Agosto de 2009 [consultado el 18 de marzo de 2022];252(2):477-85. Disponible en: https://doi.org/10.1148/radiol.2522081756
Khalafallah AA, Snarski A, Heng R, Hughes R, Renu S, Arm J, Dutchke R, Robertson IK, To LB. Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease progression and outcome: a prospective comparative study. BMJ Open [Internet]. 2013 [consultado el 18 de marzo de 2022];3(1):e002025. Disponible en: https://doi.org/10.1136/bmjopen-2012-002025
Paez D, Orellana P, Gutierrez C, Ramirez R, Mut F, Torres L. Current Status of Nuclear Medicine Practice in Latin America and the Caribbean. Journal of Nuclear Medicine [Internet]. 30 de julio de 2015 [consultado el 18 de marzo de 2022];56(10):1629-34. Disponible en: https://doi.org/10.2967/jnumed.114.148932
Hillengass J, Usmani S, Rajkumar SV, Durie BG, Mateos MV, Lonial S et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. The Lancet Oncology [Internet]. Junio de 2019 [consultado el 18 de marzo de 2022];20(6):e302-e312. Disponible en: https://doi.org/10.1016/s1470-2045(19)30309-2